Corcept Therapeutics financials
$114.74−0.77%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $761.4M | $675.0M | $482.4M | $401.9M | $366.0M | $353.9M | $306.5M | $251.2M | $159.2M | $81.3M |
| Gross profit | $748.4M | $664.2M | $475.9M | $396.5M | $360.7M | $348.3M | $301.0M | $246.0M | $155.6M | $79.3M |
| Gross margin | 98.3% | 98.4% | 98.7% | 98.7% | 98.6% | 98.4% | 98.2% | 97.9% | 97.8% | 97.5% |
| Operating income | $44.8M | $137.0M | $107.3M | $112.6M | $124.5M | $128.2M | $111.6M | $89.5M | $52.9M | $10.2M |
| Net income | $98.2M | $139.7M | $105.5M | $101.3M | $112.5M | $106.0M | $94.2M | $75.4M | $129.1M | $8.1M |
| Net margin | 12.9% | 20.7% | 21.9% | 25.2% | 30.7% | 30.0% | 30.7% | 30.0% | 81.1% | 10.0% |
| Diluted EPS | $0.82 | $1.23 | $0.94 | $0.87 | $0.89 | $0.85 | $0.77 | $0.60 | $1.04 | $0.07 |
| EBITDA | $45.9M | $137.7M | $108.3M | $113.9M | $128.0M | $128.7M | $113.8M | $89.7M | $53.0M | $10.3M |
| Operating cash flow | $142.0M | $198.3M | $126.7M | $120.3M | $167.9M | $152.0M | $136.1M | $115.7M | $60.9M | $18.4M |
| Free cash flow | $141.8M | $196.1M | $126.5M | $119.9M | $167.4M | $150.7M | $135.0M | $115.4M | $60.5M | $18.2M |
| Diluted shares | 120.0M | 113.5M | 111.7M | 116.0M | 126.0M | 124.2M | 122.6M | 126.7M | 124.5M | 116.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $120.5M | $127.7M | $135.6M | $66.3M | $77.6M | $76.2M |
| Short-term investments | $251.7M | $255.7M | $232.7M | $365.3M | $145.9M | $364.5M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $836.7M | $840.6M | $621.5M | $583.4M | $423.8M | $571.7M |
| Total liabilities | $188.8M | $161.0M | $114.8M | $81.6M | $48.0M | $48.4M |
| Shareholders' equity | $647.8M | $679.6M | $506.7M | $501.8M | $375.8M | $523.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology